Antibacterial mechanisms of polymyxin and bacterial resistance

BioMed Research International

Volumn 2015, Issue , 2015, Pages

  Yu, Zhiliang ^a   Qin, Wangrong ^a   Lin, Jianxun ^b   Fang, Shisong ^c   Qiu, Juanping ^a  

^a ZHEJIANG UNIVERSITY OF TECHNOLOGY   (China)

^b Department of Earth and Environmental Sciences   (United States)

^c SHENZHEN CENTER FOR DISEASE CONTROL AND PREVENTION   (China)

Author keywords

[No Author keywords available]

Indexed keywords

POLYMYXIN; POLYMYXIN DERIVATIVE; ANTIINFECTIVE AGENT;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; DRUG MECHANISM; DRUG SYNTHESIS; DRUG TOLERANCE; NONHUMAN; REVIEW; STRUCTURE ACTIVITY RELATION; BIOSYNTHESIS; CHEMISTRY; DRUG EFFECTS; HUMAN; MULTIDRUG RESISTANCE; SIGNAL TRANSDUCTION; SPECIES DIFFERENCE;

BACTERIA (MICROORGANISMS);

ANTI-BACTERIAL AGENTS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; HUMANS; POLYMYXINS; SIGNAL TRANSDUCTION; SPECIES SPECIFICITY;

EID: 84947648622     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2015/679109     Document Type: Review

References (83)

1. G.H. Talbot, J. Bradley, J. E. Edwards Jr., D. Gilbert, M. Scheid, and J. G. Bartlett, "Bad bugs need drugs: an update on the development pipeline from the antimicrobial availability task force of the infectious diseases society of America," Clinical Infectious Diseases, vol. 42, no. 5, pp. 657-668, 2006.
2. L. B. Rice, "Challenges in identifying new antimicrobial agents effective for treating infections with Acinetobacter baumannii and Pseudomonas aeruginosa," Clinical Infectious Diseases, vol. 43, no. 2, pp. S100-S105, 2006.
3. J. Li and R. L. Nation, "Old polymyxins are back: is resistance close?" Clinical Infectious Diseases, vol. 43, no. 5, pp. 663-664, 2006.
4. J. Li, R. L. Nation, R. J. Owen, S. Wong, O. Spelman, and C. Franklin, "Antibiograms ofmultidrug-resistant clinical Acinetobacter baumannii: promising therapeutic options for treatment of infection with colistin-resistant strains," Clinical Infectious Diseases, vol. 45, no. 5, pp. 594-598, 2007.
5. S. Biswas, J.M. Brunel, J. C. Dubus, M. Reynaud-Gaubert, and J. M. Rolain, "Colistin: an update on the antibiotic of the 21st century," Expert Review of Anti-Infective Therapy, vol. 10, no. 8, pp. 917-934, 2012.
6. A. Poudyal, B. P. Howden, J. M. Bell et al., "In vitro pharmacodynamics of colistin againstmultidrug-resistant Klebsiella pneumoniae," Journal of Antimicrobial Chemotherapy, vol. 62, no. 6, pp. 1311-1318, 2008.
7. A. P. Zavascki, L. Z. Goldani, J. Li, and R. L. Nation, "Polymyxin B for the treatment of multidrug-resistant pathogens: a critical review," Journal of Antimicrobial Chemotherapy, vol. 60, no. 6, pp. 1206-1215, 2007.
8. J. Li, R. L. Nation, R.W. Milne, J.D. Turnidge, and K. Coulthard, "Evaluationof colistin as an agent againstmulti-resistantGramnegative bacteria," International Journal ofAntimicrobialAgents, vol. 25, no. 1, pp. 11-25, 2005.
9. T. Velkov, P. E. Thompson, R. L. Nation, and J. Li, "Structureactivity relationships of polymyxin antibiotics," Journal of Medicinal Chemistry, vol. 53, no. 5, pp. 1898-1916, 2010.
10. T. Velkov, K. D. Roberts, R. L. Nation, P. E. Thompson, and J. Li, "Pharmacology of polymyxins: new insights into an "old" class of antibiotics," Future Microbiology, vol. 8, no. 6, pp. 711-724, 2013.
11. N. I. Martin, H. Hu, M. M. Moake et al., "Isolation, structural characterization, and properties of mattacin (polymyxin M), a cyclic peptide antibiotic produced by Paenibacillus kobensis M," The Journal of Biological Chemistry, vol. 278, no. 15, pp. 13124-13132, 2003.
12. C. Rausch, I. Hoof, T. Weber, W. Wohlleben, and D. H. Huson, "Phylogenetic analysis of condensation domains in NRPS sheds light on their functional evolution," BMC Evolutionary Biology, vol. 7, article 78, 2007.
13. M. Z. Ansari, G. Yadav, R. S. Gokhale, and D. Mohanty, "NRPSPKS: a knowledge-based resource for analysis of NRPS-PKS megasynthases," Nucleic Acids Research, vol. 32, pp. W405-W413, 2004.
14. S.-K. Choi, S.-Y. Park, R. Kim et al., "Identification of a polymyxin synthetase gene cluster of Paenibacillus polymyxa and heterologous expression of the gene in Bacillus subtilis," Journal of Bacteriology, vol. 191, no. 10, pp. 3350-3358, 2009.
15. H. Tsubery, H. Yaakov, S. Cohen et al., "Neopeptide antibiotics that function as opsonins and membrane-permeabilizing agents for gram-negative bacteria," Antimicrobial Agents and Chemotherapy, vol. 49, no. 8, pp. 3122-3128, 2005.
16. S. Chihara, A. Ito, and M. Yahata, "Chemical synthesis and characterization of n fattyacyl monoaminoacyl derivatives of colistin nonapeptide," Agricultural and Biological Chemistry, vol. 38, no. 10, pp. 1767-1777, 1974.
17. S. Chihara, A. Ito, andM. Yahata, "Chemical synthesis, isolation and characterization of α-N-fattyacyl colistin nonapeptide with special reference to the correlation between antimicrobial activity and carbon number of fattyacyl moiety," Agricultural and Biological Chemistry, vol. 38, no. 3, pp. 521-529, 1974.
18. S.-Y. Liao, G.-T. Ong, K.-T. Wang, and S.-H. Wu, "Conformation of polymyxin B analogs in DMSO from NMR spectra and molecular modeling," Biochimica et Biophysica Acta (BBA), vol. 1252, no. 2, pp. 312-320, 1995.
19. S. Bhattacharjya, S. A. David, V. I. Mathan, and P. Balaram, "Polymyxin B nonapeptide: conformations in water and in the lipopolysaccharide-bound state determined by twodimensional NMR and molecular dynamics," Biopolymers, vol. 41, pp. 251-265, 1997.
20. J. Mares, S. Kumaran, M. Gobbo, and O. Zerbe, "Interactions of lipopolysaccharide and polymyxin studied by NMR spectroscopy," Journal of Biological Chemistry, vol. 284, no. 17, pp. 11498-11506, 2009.
21. J. A. Orwa, C. Govaerts, R. Busson, E. Roets, A. Van Schepdael, and J. Hoogmartens, "Isolation and structural characterization of colistin components,"The Journal of Antibiotics, vol. 54, no. 7, pp. 595-599, 2001.
22. J. A. Orwa, C. Govaerts, R. Busson, E. Roets, A. Van Schepdael, and J. Hoogmartens, "Isolation and structural characterization of polymyxin B components," Journal of Chromatography A, vol. 912, no. 2, pp. 369-373, 2001.
23. K. Okimura, K. Ohki, Y. Sato, K. Ohnishi, and N. Sakura, "Semi-synthesis of polymyxin B (2-10) and colistin (2-10) analogs employing the trichloroethoxycarbonyl (Troc) group for side chain protection of α, γ-diaminobutyric acid residues," Chemical and Pharmaceutical Bulletin, vol. 55, no. 12, pp. 1724-1730, 2007.
24. N. M. Witzke and H. Heding, "Broad spectrum derivatives of polymyxin B and colistin," The Journal of Antibiotics, vol. 29, no. 12, pp. 1349-1350, 1976.
25. J. Weinstein, A. Afonso, M. Eugene Jr., and G. H. Miller, "Selective chemical modifications of polymyxin B," Bioorganic & Medicinal Chemistry Letters, vol. 8, no. 23, pp. 3391-3396, 1998.
26. K. Kanazawa, Y. Sato, K. Ohki et al., "Contribution of each amino acid residue in polymyxin b3 to antimicrobial and lipopolysaccharide binding activity," Chemical and Pharmaceutical Bulletin, vol. 57, no. 3, pp. 240-244, 2009.
27. M. Vaara, J. Fox, G. Loidl et al., "Novel polymyxin derivatives carrying only three positive charges are effective antibacterial agents," Antimicrobial Agents and Chemotherapy, vol. 52, no. 9, pp. 3229-3236, 2008.
28. H. Tsubery, I. Ofek, S. Cohen, M. Eisenstein, and M. Fridkin, "Modulation of the hydrophobic domain of polymyxin B nonapeptide: effect on outer-membrane permeabilization and lipopolysaccharide neutralization," Molecular Pharmacology, vol. 62, no. 5, pp. 1036-1042, 2002.
29. P.C. DeVisser, N.M. A. J. Kriek, P. A. V. VanHooftet al., "Solidphase synthesis of polymyxin B1 and analogues via a safetycatch approach," The Journal of Peptide Research, vol. 61, no. 6, pp. 298-306, 2003.
30. H. Tsubery, I. Ofek, S. Cohen, and M. Fridkin, "Structurefunction studies of polymyxin B nonapeptide: implications to sensitization of Gram-negative bacteria," Journal of Medicinal Chemistry, vol. 43, no. 16, pp. 3085-3092, 2000.
31. H. Tsubery, H. Yaakov, S. Cohen et al., "Neopeptide antibiotics that function as opsonins and membrane-permeabilizing agents for gram-negative bacteria," Antimicrobial Agents and Chemotherapy, vol. 49, no. 8, pp. 3122-3128, 2005.
32. V. Frecer, B. Ho, and J. L. Ding, "De novo design of potent antimicrobial peptides," Antimicrobial Agents and Chemotherapy, vol. 48, no. 9, pp. 3349-3357, 2004.
33. K. Nishino, F.-F. Hsu, J. Turk, M. J. Cromie, M.M. S.M. Wösten, and E. A. Groisman, "Identification of the lipopolysaccharide modifications controlled by the Salmonella PmrA/PmrB system mediating resistance to Fe(III) and Al(III)," Molecular Microbiology, vol. 61, no. 3, pp. 645-654, 2006.
34. H. Nikaido, "Molecular basis of bacterial outer membrane permeability revisited," Microbiology and Molecular Biology Reviews, vol. 67, no. 4, pp. 593-656, 2003.
35. C. R. H. Raetz and C. Whitfield, "Lipopolysaccharide endotoxins," Annual Review of Biochemistry, vol. 71, pp. 635-700, 2002.
36. R. E. W. Hancock and D. S. Chapple, "Peptide antibiotics," Antimicrobial Agents and Chemotherapy, vol. 43, no. 6, pp. 1317-1323, 1999.
37. J. P. Powers and R. E. Hancock, "The relationship between peptide structure and antibacterial activity," Peptides, vol. 24, no. 11, pp. 1681-1691, 2003.
38. P. Pristovšek and J. Kidrič, "The search for molecular determinants of LPS inhibition by proteins and peptides," Current Topics in Medicinal Chemistry, vol. 4, no. 11, pp. 1185-1201, 2004.
39. A. Clausell, M. Garcia-Subirats, M. Pujol, M. A. Busquets, F. Rabanal, and Y. Cajal, "Gram-negative outer and inner membrane models: insertion of cyclic cationic lipopeptides," Journal of Physical Chemistry B, vol. 111, no. 3, pp. 551-563, 2007.
40. Y. Cajal, J. Rogers, O. G. Berg, andM. K. Jain, "Intermembrane molecular contacts by polymyxin B mediate exchange of phospholipids," Biochemistry, vol. 35, no. 1, pp. 299-308, 1996.
41. A. Clausell, F. Rabanal, M. Garcia-Subirats, M. A. Alsina, and Y. Cajal, "Synthesis and membrane action of polymyxin B analogues," Luminescence, vol. 20, no. 3, pp. 117-123, 2005.
42. A. Clausell, F. Rabanal, M. Garcia-Subirats, M. A. Alsina, and Y. Cajal, "Membrane association and contact formation by a synthetic analogue of polymyxin B and its fluorescent derivatives,"The Journal of Physical Chemistry B, vol. 110, no. 9, pp. 4465-4471, 2006.
43. J. A. Imlay, "The molecular mechanisms and physiological consequences of oxidative stress: lessons from a model bacterium," Nature Reviews Microbiology, vol. 11, no. 7, pp. 443-454, 2013.
44. M. A. Kohanski, D. J. Dwyer, B. Hayete, C. A. Lawrence, and J. J. Collins, "A common mechanism of cellular death induced by bactericidal antibiotics," Cell, vol. 130, no. 5, pp. 797-810, 2007.
45. J. Yeom, J. A. Imlay, and W. Park, "Iron homeostasis affects antibiotic-mediated cell death in Pseudomonas species," The Journal of Biological Chemistry, vol. 285, no. 29, pp. 22689-22695, 2010.
46. D. J. Dwyer, M.A. Kohanski, B. Hayete, and J. J. Collins, "Gyrase inhibitors induce an oxidative damage cellular death pathway in Escherichia coli," Molecular Systems Biology, vol. 3, article 91, 2007.
47. T. R. Sampson, X. Liu, M. R. Schroeder, C. S. Kraft, E.M. Burd, and D. S. Weiss, "Rapid killing of Acinetobacter baumannii by polymyxins is mediated by a hydroxyl radical death pathway," Antimicrobial Agents and Chemotherapy, vol. 56, no. 11, pp. 5642-5649, 2012.
48. L. Fernández, C. Àlvarez-Ortega, I. Wiegand et al., "Characterization of the polymyxin B resistome of Pseudomonas aeruginosa," Antimicrobial Agents and Chemotherapy, vol. 57, no. 1, pp. 110-119, 2013.
49. S. A. Loutet, L. E. Mussen, R. S. Flannagan, and M. A. Valvano, "A two-tier model of polymyxin B resistance in Burkholderia cenocepacia," Environmental Microbiology Reports, vol. 3, no. 2, pp. 278-285, 2011.
50. L. Fernández, H. Jenssen, M. Bains, I. Wiegand, W. J. Gooderham, and R. E. W. Hancock, "The two-component system CprRS senses cationic peptides and triggers adaptive resistance in Pseudomonas aeruginosa independently of ParRS," Antimicrobial Agents and Chemotherapy, vol. 56, no. 12, pp. 6212-6222, 2012.
51. S. D. Breazeale, A. A. Ribeiro, A. L. McClerren, and C. R. H. Raetz, "A formyltransferase required for polymyxin resistance in Escherichia coli and themodification of lipidAwith 4-amino- 4-deoxy-L-arabinose: identification and function of UDP-4- deoxy-4-formamido-L-arabinose," Journal of Biological Chemistry, vol. 280, no. 14, pp. 14154-14167, 2005.
52. S. M. Moskowitz, R. K. Ernst, and S. I. Miller, "PmrAB , a two-component regulatory system of Pseudomonas aeruginosa thatmodulates resistance to cationic antimicrobial peptides and addition of aminoarabinose to lipid A," Journal of Bacteriology, vol. 186, no. 2, pp. 575-579, 2004.
53. Z. Zhou, A. A. Ribeiro, S. Lin, R. J. Cotter, S. I. Miller, and C. R. H. Raetz, "Lipid A modifications in polymyxin-resistant Salmonella typhimurium: PmrA-dependent 4-amino-4-deoxy- L-arabinose, and phosphoethanolamine incorporation," The Journal of Biological Chemistry, vol. 276, no. 46, pp. 43111-43121, 2001.
54. A. Kato, H. D. Chen, T. Latifi, and E. A. Groisman, "Reciprocal control between a bacterium's regulatory system and the modification status of its lipopolysaccharide," Molecular Cell, vol. 47, no. 6, pp. 897-908, 2012.
55. H. Lee, F.-F. Hsu, J. Turk, and E. A. Groisman, "The PmrAregulated pmrC gene mediates phosphoethanolamine modification of lipid A and polymyxin resistance in Salmonella enterica," Journal of Bacteriology, vol. 186, no. 13, pp. 4124-4133, 2004.
56. R. Tamayo, B. Choudhury, A. Septer, M. Merighi, R. Carlson, and J. S. Gunn, "Identification of cptA, a PmrA-regulated locus required for phosphoethanolamine modification of the Salmonella enterica serovar typhimurium lipopolysaccharide core," Journal of Bacteriology, vol. 187, no. 10, pp. 3391-3399, 2005.
57. M. A. Delgado, C. Mouslim, and E. A. Groisman, "The PmrA/PmrB and RcsC/YojN/RcsB systems control expression of the Salmonella O-antigen chain length determinant," Molecular Microbiology, vol. 60, no. 1, pp. 39-50, 2006.
58. M. M. Pescaretti, F. E. López, R. D. Morero, andM. A. Delgado, "The PmrA/PmrB regulatory system controls the expression of the wzzfepE gene involved in the O-antigen synthesis of Salmonella enterica serovar Typhimurium," Microbiology, vol. 157, no. 9, pp. 2515-2521, 2011.
59. J. Barchiesi, M. E. Castelli, G. DiVenanzio, M. I. Colombo, and E. G. Véscovi, "The Phop/PhoQ system and its role in Serratia marcescens pathogenesis," Journal of Bacteriology, vol. 194, no. 11, pp. 2949-2961, 2012.
60. F. C. Soncini and E. A. Groisman, "Two-component regulatory systems can interact to processmultiple environmental signals," Journal of Bacteriology, vol. 178, no. 23, pp. 6796-6801, 1996.
61. D. Shin and E. A. Groisman, "Signal-dependent binding of the response regulators PhoP and PmrA to their target promoters in vivo,"The Journal of Biological Chemistry, vol. 280, no. 6, pp. 4089-4094, 2005.
62. E. García Véscovi, F. C. Soncini, and E. A. Groisman, "Mg2+ as an extracellular signal: environmental regulation of Salmonella virulence," Cell, vol. 84, no. 1, pp. 165-174, 1996.
63. A. Kato and E. A. Groisman, "Connecting two-component regulatory systems by a protein that protects a response regulator from dephosphorylation by its cognate sensor," Genes and Development, vol. 18, no. 18, pp. 2302-2313, 2004.
64. M. M. S. M. Wösten, L. F. F. Kox, S. Chamnongpol, F. C. Soncini, and E. A. Groisman, "A signal transduction systemthat responds to extracellular iron," Cell, vol. 103, no. 1, pp. 113-125, 2000.
65. J. C. Perez and E. A. Groisman, "Acid pH activation of the PmrA/PmrB two-component regulatory system of Salmonella enterica," Molecular Microbiology, vol. 63, no. 1, pp. 283-293, 2007.
66. D. Shin, E.-J. Lee, H. Huang, and E. A. Groisman, "A positive feedback loop promotes transcription surge that jump-starts Salmonella virulence circuit," Science, vol. 314, no. 5805, pp. 1607-1609, 2006.
67. W.-S. Yeo, I. Zwir, H. V. Huang, D. Shin, A. Kato, and E. A. Groisman, "Intrinsic negative feedback governs activation surge in two-component regulatory systems," Molecular Cell, vol. 45, no. 3, pp. 409-421, 2012.
68. L. A. Arroyo, C. M. Herrera, L. Fernandez, J. V. Hankins, M. S. Trent, and R. E. W. Hancock, "The pmrCAB operon mediates polymyxin resistance in Acinetobacter baumannii ATCC 17978 and clinical isolates through phosphoethanolamine modification of lipid A," Antimicrobial Agents and Chemotherapy, vol. 55, no. 8, pp. 3743-3751, 2011.
69. C. M. Herrera, J. V. Hankins, and M. S. Trent, "Activation of PmrA inhibits LpxT-dependent phosphorylation of lipid A promoting resistance to antimicrobial peptides," Molecular Microbiology, vol. 76, no. 6, pp. 1444-1460, 2010.
70. J. S. Gunn and S. I. Miller, "PhoP-PhoQ activates transcription of pmrAB, encoding a two-component regulatory system involved in Salmonella typhimurium antimicrobial peptide resistance," Journal of Bacteriology, vol. 178, no. 23, pp. 6857-6864, 1996.
71. A. Kato, T. Latifi, and E. A. Groisman, "Closing the loop: the PmrA/PmrB two-component system negatively controls expression of its posttranscriptional activator PmrD," Proceedings of the National Academy of Sciences of the United States of America, vol. 100, no. 8, pp. 4706-4711, 2003.
72. H. P. Schweizer, "Efflux as a mechanism of resistance to antimicrobials in Pseudomonas aeruginosa and related bacteria: Unanswered questions," Genetics andMolecular Research, vol. 2, no. 1, pp. 48-62, 2003.
73. S. J. Pamp, M. Gjermansen, H. K. Johansen, and T. Tolker- Nielsen, "Tolerance to the antimicrobial peptide colistin in Pseudomonas aeruginosa biofilms is linked to metabolically active cells, and depends on the pmr and mexAB-oprM genes," Molecular Microbiology, vol. 68, no. 1, pp. 223-240, 2008.
74. E. Padilla, E. Llobet, A. Doménech-Sánchez, L. Martínez- Martínez, J. A. Bengoechea, and S. Albertí, "Klebsiella pneumoniae AcrAB efflux pump contributes to antimicrobial resistance and virulence," Antimicrobial Agents and Chemotherapy, vol. 54, no. 1, pp. 177-183, 2010.
75. D. M. Warner and S. B. Levy, "Different effects of transcriptional regulators MarA, SoxS and Rob on susceptibility of Escherichia coli to cationic antimicrobial peptides (CAMPs): rob-dependent CAMP induction of the marRAB operon," Microbiology, vol. 156, no. 2, pp. 570-578, 2010.
76. C. C. Fehlner-Gardiner and M. A. Valvano, "Cloning and characterization of the Burkholderia vietnamiensis norM gene encoding a multi-drug efflux protein," FEMS Microbiology Letters, vol. 215, no. 2, pp. 279-283, 2002.
77. E. L. A. Macfarlane, A. Kwasnicka, M. M. Ochs, and R. E. W. Hancock, "PhoP-PhoQ homologues in Pseudomonas aeruginosa regulate expression of the outer-membrane protein OprH and polymyxin B resistance,"MolecularMicrobiology, vol. 34, no. 2, pp. 305-316, 1999.
78. P. Jeannin, G. Magistrelli, L. Goetsch et al., "Outer membrane protein A ( OmpA ): a new pathogen-associated molecular pattern that interacts with antigen presenting cells-impact on vaccine strategies," Vaccine, vol. 20, no. 4, pp.A23-A27, 2002.
79. E. Llobet, C. March, P. Giménez, and J. A. Bengoechea, "Klebsiella pneumoniae OmpA confers resistance to antimicrobial peptides," Antimicrobial Agents and Chemotherapy, vol. 53, no. 1, pp. 298-302, 2009.
80. M. A. Campos, M. A. Vargas, V. Regueiro, C. M. Llompart, S. Albertí, and J. A. Bengoechea, "Capsule polysaccharide mediates bacterial resistance to antimicrobial peptides," Infection and Immunity, vol. 72, no. 12, pp. 7107-7114, 2004.
81. E. Llobet, J. M. Tomás, and J. A. Bengoechea, "Capsule polysaccharide is a bacterial decoy for antimicrobial peptides," Microbiology, vol. 154, no. 12, pp. 3877-3886, 2008.
82. J. H. Moffatt, M. Harper, P. Harrison et al., "Colistin resistance in Acinetobacter baumannii is mediated by complete loss of lipopolysaccharide production," Antimicrobial Agents and Chemotherapy, vol. 54, no. 12, pp. 4971-4977, 2010.
83. J. H. Moffatt, M. Harper, B. Adler, R. L. Nation, J. Li, and J. D. Boyce, "Insertion sequence IS Aba11 is involved in colistin resistance and loss of lipopolysaccharide in Acinetobacter baumannii," Antimicrobial Agents and Chemotherapy, vol. 55, no. 6, pp. 3022-3024, 2011.